- Live weather radar
- Wildcats continue spring season against UTEP Miners
- Judge rules feds can try BP agent in Nogales cross-border shooting
- Police & fire scanners
- Report road hazards, graffiti & other issues
- A note to UA's new president: In my day, we didn't have 'safe places'7
- Lawyer: BP 'lost or destroyed' original video of Nogales cross-border shooting1
- Shafer withdraws as candidate for TUSD interim sup't1
- TUSD set to hire interim leaders after apparent open meeting law violation1
- JCPenney may close El Con store1
Posted May 7, 2012, 12:23 pm
Arizona will receive nearly $2 million of a $100 million, multi-state settlement with Abbott Laboratories over allegations of illegal off-label marketing for the drug Depakote, state Attorney General Tom Horne announced Monday.
In addition, Abbott will pay a $700 million criminal penalty and will plead guilty to one misdemeanor count of violating the Food, Drug and Cosmetic Act for misbranding, the company said in a press release Monday.
The agreement is the largest-ever consumer protection-based settlement with a pharmaceutical company, said Amy Rezzonico, spokeswoman for the Arizona Attorney General's Office.
Depakote is approved by the Food and Drug Administration for the treatment of seizure disorders, bipolar disorder, and migraines. The lawsuit alleged Abbott marketed the medication for schizophrenia, agitated dementia, and autism, which were not FDA-approved.
In the complaint filed Monday with the settlement, Arizona, 43 other states and the District of Columbia alleged unfair and deceptive practices when the company marketed Depakote for those unapproved uses, Rezzonico said.
Abbott agreed to change its marketing of the drug and to no longer promote off-label use. It agreed to pay $100 million in the settlement, of which Arizona will receive $1,964,188 that will be placed in the state's Consumer Fraud Revolving Fund, Rezzonico said.
“Consumers need to be able to trust the health care system, and that includes ensuring that pharmaceutical companies market their products appropriately,” Horne said in a press release. “This settlement shows that this office and my colleagues nationwide will not tolerate the improper marketing of medicines that affect peoples’ physical and mental well-being.”
Under the settlement, Abbott will be:
For a five-year period Abbott must:
Other than Arizona, Attorneys General of the District of Columbia and the following states also participated in Monday’s settlement: Alabama, Alaska, Arkansas, California, Colorado, Connecticut, Florida, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia and Wisconsin.